At a glance
ClinicalIndex Comparison RecordPhase 2Active· 264 enrolled
Drug / intervention
Olaparib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Olaparib, MEDI4736, and 1 other intervention for Ovarian and 3 related conditions. Active but no longer recruiting, targeting 264 participants across 47 sites in 7 countries.
Detailed Summary
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian, Breast, SCLC, Gastric Cancers
CountriesFrance, Israel, Netherlands, South Korea, Switzerland, United Kingdom, United States
CollaboratorsIQVIA Pty Ltd
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
Enrollment StartMar 2016
First PostedApr 2016
Primary CompletionSep 2021
TodayJul 2026
Study CompletionSep 2026
First PostedApr 12, 2016
Enrollment StartMar 17, 2016
Primary CompletionSep 17, 2021
Study CompletionSep 17, 2026
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 10.2 years ago
Interventions
Olaparibdrug
Olaparib
MEDI4736drug
MEDI4736
Bevacizumabdrug
Bevacizumab